Fourteen out of 21 quinoxaline derivatives described in the present paper were selected at NCI for evaluation of their in vitro anticancer activity. Preliminary screening showed that some derivatives exhibited a moderate to strong growth inhibition activity on various tumor panel cell lines between 10–5 and 10–4 M concentrations. Interesting selectivities were also recorded between 10–8 and 10–6 M for the compounds 9 and 13.
